Menu
← Oncology Approval Tracker
FDA DECISION ·
Imfinzi + gemcitabine and cisplatin
durvalumab plus gemcitabine and cisplatin · AstraZeneca
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with locally advanced or metastatic biliary tract cancer treated with durvalumab in combination with gemcitabine and cisplatin.
LAMPGEN ANALYSIS
Why it matters
The action adds a PD-L1 inhibitor to a platinum-gemcitabine backbone for advanced biliary tract cancers.
What research teams should watch
Capture the biliary primary site and align chemotherapy cycle dates, maintenance transition and immune toxicity follow-up.
PRIMARY RECORDS